Novartis

Conatus Pharma to explore options as liver disease drug fails trial
Conatus Pharma to explore options as liver disease drug fails trial
Yahoo/Reuters
Conatus Pharmaceuticals
clinical trials
NASH
emricasan
Novartis
Flag link:
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Fierce Pharma
Novartis
Mayzent
JNJ
Spravato
ICER
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Chutes & Ladders—Novartis says hello to new pharma chief
Chutes & Ladders—Novartis says hello to new pharma chief
Fierce Biotech
Novartis
Marie-France Tschudin
Flag link:
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
Fierce Pharma
drug pricing
GoodRx
Novartis
Spark Therapeutics
Zolgensma
Luxturna
Flag link:
Novartis Close to Settling Kickback Violations, Filing Inadvertently Shows
Novartis Close to Settling Kickback Violations, Filing Inadvertently Shows
BioSpace
Novartis
fraud
kickbacks
physician gifts
Medicare
Medicaid
Flag link:
Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study
Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study
Pharmaceutical Business Review
Novartis
Cosentyx
clinical trials
psoriatic arthritis
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:
The gene therapy era has arrived. So have the challenges.
The gene therapy era has arrived. So have the challenges.
Biopharma Dive
cell therapy
gene therapy
FDA
regulatory
Novartis
Zolgensma
Flag link:
A struggling Sanofi is preparing to hire Novartis senior pharma exec Paul Hudson as new CEO, replacing Brandicourt -- report
A struggling Sanofi is preparing to hire Novartis senior pharma exec Paul Hudson as new CEO, replacing Brandicourt -- report
Endpoints
Sanofi
Pharma CEOs
Novartis
Paul Hudson
Olivier Brandicourt
Flag link:
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
Flag link:
Is $2.1 million too much for a drug? For affected parents, there is no debate
Is $2.1 million too much for a drug? For affected parents, there is no debate
Stat
Novartis
drug pricing
Zolgensma
SMA
Flag link:
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Research Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Fierce Biotech
ASCO 2019
Ayala Pharmaceuticals
Novartis
triple negative breast cancer
AL101
Flag link:
ASCO 2019 day three
ASCO 2019 day three
Pharmaforum
ASCO 2019
Merck
AstraZeneca
pancreatic cancer
Novartis
alpelisib
Roche
entrectinib
Flag link:
ASCO 2019 day two
ASCO 2019 day two
Pharmaforum
Gilead Sciences
Kite Pharma
KTE-X19
CAR-T
ASCO 2019
Novartis
Merck
Keytruda
spartalizumab
Flag link:
ASCO: Novartis' Kisqali posts first-in-class survival win in younger women
ASCO: Novartis' Kisqali posts first-in-class survival win in younger women
Fierce Pharma
breast cancer
ASCO 2019
Novartis
clinical trials
Kisqali
Flag link:
Why Concerns About a “Break Down” in Drug Pricing Are Misplaced
Why Concerns About a “Break Down” in Drug Pricing Are Misplaced
BIOTechNow
FDA
Novartis
drug pricing
Flag link:
Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
Motley Fool
Novartis
Zolgensma
SMA
gene therapy
Flag link:
Novartis burnishes prospects for its big asthma drug with positive PhIII data from a similar treatment
Novartis burnishes prospects for its big asthma drug with positive PhIII data from a similar treatment
Endpoints
Novartis
asthma
QMF149
clinical trials
Flag link:
ASCO 2019 Preview: Presentations to Keep An Eye On
ASCO 2019 Preview: Presentations to Keep An Eye On
BioSpace
ASCO 2019
Novartis
Oncoceutics
OncoNano Medicine
AstraZeneca
Flag link:

Pages